The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 25, 2022
Filed:
Aug. 21, 2017
Applicant:
Akeso Biopharma, Inc., Guangdong, CN;
Inventors:
Baiyong Li, Guangdong, CN;
Yu Xia, Guangdong, CN;
Peng Zhang, Guangdong, CN;
Xinghua Pang, Guangdong, CN;
Zhongmin Wang, Guangdong, CN;
Assignee:
Akeso Biopharma, Inc., Guangdong, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 5/12 (2006.01); C12N 15/63 (2006.01); C12N 15/85 (2006.01); G01N 33/52 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); G01N 33/541 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 39/001129 (2018.08); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C12N 5/12 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01); G01N 33/52 (2013.01); G01N 33/53 (2013.01); G01N 33/541 (2013.01); G01N 33/6863 (2013.01); A61K 38/00 (2013.01); A61K 39/001111 (2018.08); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/40 (2013.01); C12N 2015/8518 (2013.01);
Abstract
The present invention belongs to the fields of tumor therapy and molecular immunology. The present invention relates to an anti-CTLA4 antibody, pharmaceutical composition and use thereof. The anti-CTLA4 antibody of the present invention can specifically bind CTLA4, and can very effectively block the binding of CLTA4 to B7.